|
Press Releases |
|
 |
|
Monday, June 2, 2025 |
|
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan |
Eisai Co., Ltd. announced today the launch of "Pariet S" (pharmaceutical requiring guidance), which is highly effective in alleviating severe heartburn andstomach pain caused by gastric acid reflux, at pharmacies and drugstores throughout Japan.(1) more info >> |
|
Wednesday, May 28, 2025 |
|
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China |
Eisai Co., Ltd. announced today that the in-house-discovered and developed orexin receptor antagonist DAYVIGO (generic name: lemborexant) has been approved in China for the treatment of adults with insomnia, characterized by difficulties with sleep onset and/or sleep maintenance. more info >> |
|
Wednesday, May 21, 2025 |
|
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025 |
Eisai Co., Ltd. announced today the presentation of clinical research across its oncology portfolio and pipeline during the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting (#ASCO25), which is taking place in Chicago, Illinois, and virtually,from May 30 to June 3. more info >> |
|
Friday, May 16, 2025 |
|
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro |
Eisai Co., Ltd. announced today that it has received notification from Japan's Ministry of Health, Labour, and Welfare (MHLW) that the "all-case surveillance" post-marketing observational study condition required at the time of approval of anticancer agent "Remitoro for Intravenous Drip Infusion 300microgram" (Denileukin Diftitox (Genetical Recombination)) for the indications of T-cell Lymphoma has been cleared. more info >> |
|
Wednesday, April 30, 2025 |
|
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star |
Eisai Co., Ltd. announced today that its Representative Corporate Officer and CEO Haruo Naito has been selected to receive the Order of the Rising Sun, Gold and Silver Star at the 2025 Spring Conferment of Decorations. more info >> |
|
Friday, April 18, 2025 |
|
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union |
Eisai Co., Ltd. and Biogen Inc. announced today that the European Commission (EC) has granted the amyloid-beta (Aβ) monoclonal antibody Leqembi (lecanemab) Marketing Authorization (MA) in the European Union (EU). more info >> |
|
Tuesday, April 1, 2025 |
|
Eisai to Divest Rights for Pariet in China to Peak Pharma |
Eisai Co., Ltd. announced today that it has entered into an agreement to divest the rights for proton pump inhibitor Pariet (generic name: rabeprazole sodium) in China to Beijing Peak Biology Pharmaceuticals Co., Ltd., a CBC Group-controlled company. more info >> |
|
Tuesday, March 25, 2025 |
|
World's First Early Alzheimer's Disease Treatment Developed in Japan LEQEMBI Receives Prime Minister's Award at the 12th Technology Management and Innovation Awards |
Eisai Co., Ltd. announced today that humanized anti- soluble aggregated amyloid-beta (Aβ) monoclonal antibody "LEQEMBI" (lecanemab) for the treatment of early Alzheimer's disease (early AD ) has received the Prime Minister's Award at the 12th Technology Management and Innovation Awards hosted by the Japan Techno-Economics Society (JATES). more info >> |
|
Eisai Selected as a Nadeshiko Brand 2025 as a Listed Company Excelling in Promotion of Women in the Workplace |
Eisai Co., Ltd. announced today that it has been selected by the Ministry of Economy, Trade and Industry (METI) and the Tokyo Stock Exchange (TSE) as a Nadeshiko Brand 2025 as a listed company excelling in the promotion of women in the workplace. more info >> |
|
Monday, March 10, 2025 |
|
Eisai Recognized as "2025 Kenko Investment for Health" for the First Time and Certified as "Outstanding Organization Of Kenko Investment for Health Program (White 500)" for the Sixth Time |
Eisai Co., Ltd. announced today that it has been recognized as the 2025 KENKO Investment for Health by Japan's Ministry of Economy, Trade, and Industry (METI) and the Tokyo Stock Exchange, for the first time as a company strategically carrying out efforts with regard to its employees' health from a management perspective. more info >> |
|
|
|
|
|
|
|
|
 |
Latest Press Releases |
 |
The Future Is Now! The Philippines Leads the AI-Powered Cloud Revolution
Jul 2, 2025 08:59 HKT/SGT
|
|
|
DASA, Latin America's Largest Diagnostic Provider, Selects AGFA HealthCare's Enterprise Imaging Platform in Flagship Agreement
Jul 1, 2025 16:00 HKT/SGT
|
|
|
JCB and Mandai Wildlife Group Deepen Partnership with exclusive discounts for JCB cardmembers
Jul 1, 2025 16:00 JST
|
|
|
GFEAI 2025 Concludes Successfully: PM Paetongtarn Backs Human-Centric AI, AIGPC Emerges as Regional AI Ethics Hub
Jul 1, 2025 14:40 HKT/SGT
|
|
|
Fujitsu provides Japan's first AI-powered cloud-based library search service
Jul 1, 2025 11:30 JST
|
|
|
JCB Brings Apple Pay to Cardmembers in Vietnam
Jul 1, 2025 11:15 JST
|
|
|
First Shipment of LNG from the LNG Canada Project
Jul 1, 2025 11:00 JST
|
|
|
Chinabank Fully Transitions Into AI-powered Human Capital Management
Jul 1, 2025 08:00 HKT/SGT
|
|
|
HKIRA Announces Winners of the 11th IR Awards 2025
Jul 1, 2025 00:20 HKT/SGT
|
|
|
Approval in Principle (AiP) for World's First LCO2 / Methanol Carrier
Jun 30, 2025 20:30 JST
|
|
|
Acropolis Rally Greece: Day 4 Sunday success and second overall for TOYOTA GAZOO Racing's Ogier
Jun 30, 2025 20:15 JST
|
|
|
Mitsubishi Fuso-Hino Merger: 4 Firms Collaborate for the Future of Commercial Vehicles
Jun 30, 2025 20:10 JST
|
|
|
Six Companies Establish BlueRebirth Council to Expand Use of Recycled Materials in New Vehicles
Jun 30, 2025 19:25 JST
|
|
|
Honda Changes Plan to Build New Production Plant for Next-generation Fuel Cell Module in Japan
Jun 30, 2025 19:20 JST
|
|
|
MHI-AC&R Receives Recommendation Award of JARAC's 42nd Excellent Energy Saving Equipment Awards
Jun 30, 2025 19:00 JST
|
|
|
|
More Press release >> |
|
|
 |
 |
 |
|
|